Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy

Journal of Clinical Oncology

Volumn 31, Issue 29, 2013, Pages 3664-3672

  Sinicrope, Frank A ^a   Mahoney, Michelle R ^a   Smyrk, Thomas C ^a   Thibodeau, Stephen N ^a   Warren, Robert S ^b   Bertagnolli, Monica M ^c   Nelson, Garth D ^a   Goldberg, Richard M ^d   Sargent, Daniel J ^a   Alberts, Steven R ^a  

^a MAYO CLINIC CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; MUTL PROTEIN HOMOLOG 1; OXALIPLATIN; PROTEIN MSH2; PROTEIN MSH6; TUMOR MARKER; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PLATINUM COMPLEX; RAS PROTEIN;

ADULT; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; COLON CANCER; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MISMATCH REPAIR; PRIORITY JOURNAL; PROGNOSTIC ASSESSMENT; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; ADJUVANT CHEMOTHERAPY; AGED; COLONIC NEOPLASMS; GENETICS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DNA MISMATCH REPAIR; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 84891619188     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.48.9591     Document Type: Conference Paper

References (42)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Howlader N, Noone AM, Krapcho M, et al: SEER cancer statistics review, 1975-2009 (vintage 2009 populations). http://seer.cancer.gov/csr/1975-2009-pops09/
3. Ionov Y, Peinado MA, Malkhosyan S, et al: Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 363:558-561, 1993
4. Thibodeau SN, Bren G, Schaid D: Microsatellite instability in cancer of the proximal colon. Science 260:816-819, 1993
5. Herman JG, Umar A, Polyak K, et al: Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95:6870-6875, 1998
6. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96:8681-8686, 1999
7. Domingo E, Niessen RC, Oliveira C, et al: BRAFV600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 24:3995-3998, 2005
8. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417:949-954, 2002
9. Rajagopalan H, Bardelli A, Lengauer C, et al: Tumorigenesis: RAF/RAS oncogenes and mismatchrepair status. Nature 418:934, 2002
10. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096, 2009
11. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
12. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862, 2011
13. Jass JR, Do KA, Simms LA, et al: Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42:673-679, 1998
14. Ribic CM, Sargent DJ, Moore MJ, et al: Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247-257, 2003
15. Samowitz WS, Curtin K, Ma KN, et al: Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10:917-923, 2001
16. Sinicrope FA, Foster NR, Thibodeau SN, et al: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 103:863-875, 2011
17. Popat S, Hubner R, Houlston RS: Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618, 2005
18. André T, Boni C, Navarro M, et al: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109-3116, 2009
19. Carethers JM, Chauhan DP, Fink D, et al: Mismatch repair proficiency and in vitro response to 5-fluorouracil. Gastroenterology 117:123-131, 1999
20. Pocard M, Bras-Gonçalves R, Hamelin R, et al: Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: Influence of P53 status. Anticancer Res 20:85-90, 2000
21. Sargent DJ, Marsoni S, Monges G, et al: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28:3219-3226, 2010
22. Fink D, Nebel S, Aebi S, et al: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881-4886, 1996
23. Alberts SR, Sargent DJ, Nair S, et al: Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: A randomized trial. JAMA 307:1383-1393, 2012
24. Gryfe R, Kim H, Hsieh ET, et al: Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77, 2000
25. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28:466-474, 2010
26. Koopman M, Kortman GA, Mekenkamp L, et al: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 100:266-273, 2009
27. Bertagnolli MM, Niedzwiecki D, Compton CC, et al: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 27:1814-1821, 2009
28. Sinicrope FA, Rego RL, Garrity-Park MM, et al: Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instability. Int J Cancer 120:1232-1238, 2007
29. Domingo E, Laiho P, Ollikainen M, et al: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 41: 664-668, 2004
30. Angulo B, García-García E, Martínez R, et al: A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: A morphology-based approach in colorectal carcinoma. J Mol Diagn 12:292-299, 2010
31. Ogino S, Meyerhardt JA, Irahara N, et al: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 15:7322-7329, 2009
32. Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 18:890-900, 2012
33. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
34. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
35. R Development Core Team: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2011
36. Greene FL, Stewart AK, Norton HJ: A new TNM staging strategy for node-positive (stage III) colon cancer: An analysis of 50,042 patients. Ann Surg 236:416-421, 2002
37. Hutchins G, Southward K, Handley K, et al: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29:1261-1270, 2011
38. Gavin PG, Colangelo LH, Fumagalli D, et al: Mutation profiling and microsatellite instability in stage II and III colon cancer: An assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18:6531-6541, 2012
39. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J Clin Oncol 27:5931-5937, 2009
40. Roth AD, Delorenzi M, Tejpar S, et al: Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer. J Natl Cancer Inst 104:1635-1646, 2012
41. Sinicrope FA, Shi Q: Combining molecular markers with the TNM staging system to improve prognostication in stage II and III colon cancer: Are we ready yet? J Natl Cancer Inst 104:1616-1618, 2012
42. Sargent DJ, Wieand HS, Haller DG, et al: Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664-8670, 2005